FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2165447220> ?p ?o ?g. }

• W2165447220 endingPage "11384" @default.
• W2165447220 startingPage "11384" @default.
• W2165447220 abstract "To demonstrate that administering heparanase inhibitor PI-88 at 160 mg/d is safe and promising in reducing hepatocellular carcinoma (HCC) recurrence for up to 3 year following curative resection.A total of 143 patients (83.1% of the 172 participants in the phase II study) participated in the follow-up study. Of these patients, 50 had received no treatment, 48 had received 160 mg/d PI-88, and 45 had received 250 mg/d PI-88 during the phase II trial. Safety parameters and the following efficacy endpoints were investigated: (1) time to recurrence; (2) disease-free survival; and (3) overall survival.PI-88 at 160 mg/d delayed the onset and frequency of HCC recurrence, and provided a clinically significant survival advantage for up to 3 years after treatment compared with those of the control group: (1) the recurrence-free rate increased from 50% to 63%, and (2) time to recurrence at the 36th percentile was postponed by 78%. The efficacy of administering PI-88 at 250 mg/d was confounded by a high dropout rate (11 out of 54 patients). Additionally, subgroup analyses of patients with (1) multiple tumors or a single tumor ≥ 2 cm; and (2) hepatitis B or C revealed that administering PI-88 at 160 mg/d conferred the most significant survival advantage (56.8% improvement in disease-free survival, P = 0.045) for patients with both risk factors for recurrence.Administering PI-88 at 160 mg/d is a safe and well-tolerated dosage that may confer significant clinical benefits for patients with HCC." @default.
• W2165447220 created "2016-06-24" @default.
• W2165447220 creator A5009124766 @default.
• W2165447220 creator A5017113195 @default.
• W2165447220 creator A5018686864 @default.
• W2165447220 creator A5021689254 @default.
• W2165447220 creator A5023616567 @default.
• W2165447220 creator A5037360770 @default.
• W2165447220 creator A5039778548 @default.
• W2165447220 creator A5042881623 @default.
• W2165447220 creator A5047059319 @default.
• W2165447220 creator A5047570880 @default.
• W2165447220 creator A5051675160 @default.
• W2165447220 creator A5058253583 @default.
• W2165447220 creator A5064282719 @default.
• W2165447220 creator A5064868087 @default.
• W2165447220 creator A5066224634 @default.
• W2165447220 creator A5067213569 @default.
• W2165447220 creator A5069232007 @default.
• W2165447220 creator A5072593323 @default.
• W2165447220 creator A5078163693 @default.
• W2165447220 date "2014-01-01" @default.
• W2165447220 modified "2023-10-17" @default.
• W2165447220 title "Adjuvant heparanase inhibitor PI-88 therapy for hepatocellular carcinoma recurrence" @default.
• W2165447220 cites W1963805168 @default.
• W2165447220 cites W1971837077 @default.
• W2165447220 cites W1972114838 @default.
• W2165447220 cites W1994193851 @default.
• W2165447220 cites W1998453897 @default.
• W2165447220 cites W2006570056 @default.
• W2165447220 cites W2015407907 @default.
• W2165447220 cites W2020113016 @default.
• W2165447220 cites W2037832501 @default.
• W2165447220 cites W2059530905 @default.
• W2165447220 cites W2064399851 @default.
• W2165447220 cites W2087980926 @default.
• W2165447220 cites W2104287351 @default.
• W2165447220 cites W2109065012 @default.
• W2165447220 cites W2123528734 @default.
• W2165447220 cites W2132478764 @default.
• W2165447220 cites W2153935627 @default.
• W2165447220 cites W4243625103 @default.
• W2165447220 doi "https://doi.org/10.3748/wjg.v20.i32.11384" @default.
• W2165447220 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4145780" @default.
• W2165447220 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/25170226" @default.
• W2165447220 hasPublicationYear "2014" @default.
• W2165447220 type Work @default.
• W2165447220 sameAs 2165447220 @default.
• W2165447220 citedByCount "53" @default.
• W2165447220 countsByYear W21654472202014 @default.
• W2165447220 countsByYear W21654472202015 @default.
• W2165447220 countsByYear W21654472202016 @default.
• W2165447220 countsByYear W21654472202017 @default.
• W2165447220 countsByYear W21654472202018 @default.
• W2165447220 countsByYear W21654472202019 @default.
• W2165447220 countsByYear W21654472202020 @default.
• W2165447220 countsByYear W21654472202021 @default.
• W2165447220 countsByYear W21654472202022 @default.
• W2165447220 countsByYear W21654472202023 @default.
• W2165447220 crossrefType "journal-article" @default.
• W2165447220 hasAuthorship W2165447220A5009124766 @default.
• W2165447220 hasAuthorship W2165447220A5017113195 @default.
• W2165447220 hasAuthorship W2165447220A5018686864 @default.
• W2165447220 hasAuthorship W2165447220A5021689254 @default.
• W2165447220 hasAuthorship W2165447220A5023616567 @default.
• W2165447220 hasAuthorship W2165447220A5037360770 @default.
• W2165447220 hasAuthorship W2165447220A5039778548 @default.
• W2165447220 hasAuthorship W2165447220A5042881623 @default.
• W2165447220 hasAuthorship W2165447220A5047059319 @default.
• W2165447220 hasAuthorship W2165447220A5047570880 @default.
• W2165447220 hasAuthorship W2165447220A5051675160 @default.
• W2165447220 hasAuthorship W2165447220A5058253583 @default.
• W2165447220 hasAuthorship W2165447220A5064282719 @default.
• W2165447220 hasAuthorship W2165447220A5064868087 @default.
• W2165447220 hasAuthorship W2165447220A5066224634 @default.
• W2165447220 hasAuthorship W2165447220A5067213569 @default.
• W2165447220 hasAuthorship W2165447220A5069232007 @default.
• W2165447220 hasAuthorship W2165447220A5072593323 @default.
• W2165447220 hasAuthorship W2165447220A5078163693 @default.
• W2165447220 hasBestOaLocation W21654472201 @default.
• W2165447220 hasConcept C121608353 @default.
• W2165447220 hasConcept C126322002 @default.
• W2165447220 hasConcept C141071460 @default.
• W2165447220 hasConcept C143998085 @default.
• W2165447220 hasConcept C2777382497 @default.
• W2165447220 hasConcept C2777863537 @default.
• W2165447220 hasConcept C2777982462 @default.
• W2165447220 hasConcept C2778019345 @default.
• W2165447220 hasConcept C71924100 @default.
• W2165447220 hasConcept C90924648 @default.
• W2165447220 hasConceptScore W2165447220C121608353 @default.
• W2165447220 hasConceptScore W2165447220C126322002 @default.
• W2165447220 hasConceptScore W2165447220C141071460 @default.
• W2165447220 hasConceptScore W2165447220C143998085 @default.
• W2165447220 hasConceptScore W2165447220C2777382497 @default.
• W2165447220 hasConceptScore W2165447220C2777863537 @default.
• W2165447220 hasConceptScore W2165447220C2777982462 @default.
• W2165447220 hasConceptScore W2165447220C2778019345 @default.

• next